Last update 08 May 2025

Chia Tai Tianqing (Guangzhou) Pharmaceutical Co., Ltd

Private Company|2023|Guangdong Sheng, China

Overview

Tags

Otorhinolaryngologic Diseases
Immune System Diseases
Digestive System Disorders
Small molecule drug
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms1
Immune System Diseases1
Hemic and Lymphatic Diseases1
Infectious Diseases1
Top 5 Drug TypeCount
Small molecule drug1
Monoclonal antibody1
Top 5 TargetCount
LAG3 x PD-11
GR(Glucocorticoid receptor)1

Related

2
Drugs associated with Chia Tai Tianqing (Guangzhou) Pharmaceutical Co., Ltd
Budesonide
Target
GR
Mechanism
GR agonists
Active Org.
Calliditas Therapeutics ABCalliditas Therapeutics AB [+31]
Originator Org.
AstraZeneca Pharmaceuticals Co. Ltd.AstraZeneca Pharmaceuticals Co. Ltd.
Active Indication
Glomerulonephritis, IGA [+9]
Inactive Indication
Acute Graft Versus Host Disease [+21]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.-
First Approval Date01 Oct 1981
TQB-2223/Penpulimab
Target
LAG3 x PD-1
Mechanism
LAG3 inhibitors [+1]
Active Org.
Chia Tai Tianqing (Guangzhou) Pharmaceutical Co., Ltd [+1]
Originator Org.
Chia Tai Tianqing (Guangzhou) Pharmaceutical Co., Ltd
Active Indication
Advanced Malignant Solid Neoplasm [+1]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
2
Clinical Trials associated with Chia Tai Tianqing (Guangzhou) Pharmaceutical Co., Ltd
CTR20244299
/ Active, not recruitingPhase 1
TQC3301吸入喷雾剂在中国健康参与者中的安全性、耐受性及药代动力学的I期临床研究 。
[Translation] A phase I clinical study of the safety, tolerability and pharmacokinetics of TQC3301 inhalation spray in healthy Chinese participants.
CTR20243867
/ RecruitingPhase 1
评估TQB2252注射液在晚期恶性肿瘤受试者中安全性和药代动力学的多中心、开放的I期临床试验
[Translation] A multicenter, open-label Phase I clinical trial to evaluate the safety and pharmacokinetics of TQB2252 injection in subjects with advanced malignant tumors
100 Clinical Results associated with Chia Tai Tianqing (Guangzhou) Pharmaceutical Co., Ltd
Login to view more data
0 Patents (Medical) associated with Chia Tai Tianqing (Guangzhou) Pharmaceutical Co., Ltd
Login to view more data
100 Deals associated with Chia Tai Tianqing (Guangzhou) Pharmaceutical Co., Ltd
Login to view more data
100 Translational Medicine associated with Chia Tai Tianqing (Guangzhou) Pharmaceutical Co., Ltd
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
2
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
TQB-2223/Penpulimab
 ( LAG3 x PD-1 )		Advanced Malignant Solid Neoplasm
More
Phase 1
Budesonide
 ( GR )		Asthma
More
Phase 1
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free